Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002962 (angina)
 21,142 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Obsidan was tested for effects on psychoemotional stress (PES) tolerance in 37 patients with coronary heart disease concurrent with angina pectoris. During PES testing, the course treatment of obsidan versus placebo resulted in a significant decrease in the pulse-pressure index by significantly bringing down heart rate. With this, blood pressure remained unchanged. The patients who were highly responsive to PES, as evidenced by heart rate measurement, showed a high rise in systolic and diastolic blood pressure when they were taking obsidan. The frequency of positive tests was 48.7% before obsidan therapy and 8.1% during its therapy; that was 29.8 and 8.1%, respectively, when the objective criterion for myocardial ischemia was used as ECG ST-segment displacement.
 ...
PMID:[Effects of obsidan on hemodynamic indices and clinical manifestations of angina pectoris in patients with ischemic heart disease during psychoemotional stress]. 204 Dec 84

Doses of 80, 160 and 320 mg of Inderal LA (slow-release propranolol) were compared in 12 patients with stable angina pectoris. There was an unpredictable and variable individual response to treatment and hence no differences were detected between the effects of the three doses on mean treadmill exercise duration, time to angina, frequency of angina or glyceryl/trinitrate consumption. There was a marked deterioration in two patients whilst on 320 mg Inderal LA. In these patients, the time to angina fell by 2 minutes 50 seconds and 4 minutes 20 seconds on 320 mg daily and 160 mg daily respectively. Given the inter-patient variability in response to Inderal LA, the dose for each patient should be individually titrated according to response. Two patients reported here suggest that some subjects may benefit from lower doses, although further work is required to clarify this point. Possible explanations for this finding are discussed.
 ...
PMID:Comparison of the effectiveness of slow-release propranolol (Inderal LA) 80, 160 and 320 mg orally daily in the treatment of angina pectoris. 231 42

Management of patients with chest pain and hypothyroidism is a clinical dilemma. Thyroid replacement therapy may exacerbate angina pectoris. Administration of a beta blocker such as propranolol (Inderal) concomitantly with thyroid replacement therapy is useful in treatment of angina. However, beta blockers can induce variant angina owing to increased norepinephrine secretion and enhanced alpha-mediated responsiveness in the hypothyroid state. Hypotension and syncopal episodes may develop in the hypothyroid patient after administration of nitrates. Cardiac catheterization and revascularization are well tolerated by myxedematous patients with angina. After surgery, full thyroid replacement therapy should be initiated gradually and with caution.
 ...
PMID:Hypothyroidism with angina pectoris. A clinical dilemma. 308 77

In the treatment of angina pectoris a double-blind evaluation of verapamil (Cordilox) at two dose levels-namely, 80 mg thrice daily and 120 mg thrice daily-propranolol (Inderal) 100 mg thrice daily, and isosorbide dinitrate (Vascardin) 20 mg thrice daily has been made against a placebo. The assessment was based on relief from daily attacks of angina on effort and the response to a whole-body exercise test. We can find no statistically significant difference between the effects of verapamil (120 mg three times a day) and propranolol (100 mg three times a day) in the treatment of angina of effort. Both of these preparations are more effective than a placebo both in the reduction of daily attacks (P < 0.01) and in the prolongation of exercise test (P < 0.05). Isosorbide dinitrate (20 mg three times a day) appears to be no more effective than a placebo in the treatment of angina on effort, but 14 out of 32 patients experienced headache of such severity that even when the dose was reduced to 10 mg thrice daily this drug therapy had to be withdrawn. Both propranolol (100 mg three times a day) and verapamil (120 mg three times a day) had a significant lowering effect on the diastolic blood pressure as measured with the patient standing (P < 0.01).
 ...
PMID:Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. 457 Jun 71

Traditionally when considering the pharmacologic basis of therapy in angina pectoris, attention is focussed on alterations of coronary blood flow. Yet the diseased coronary arteries in these patients often do not appear to be capable of responding to vasodilatory drugs. Since the pain of myocardial ischemia is relieved by a number of interventions without an increase in coronary blood flow, the concept herein considered is that angina pector is best viewed as an unfavorable relation between myocardial oxygen requirements and availability. Thus, the clinical value of the major antianginal agents is thought to be based importantly upon their actions to reduce myocardial oxygen consumption rather than to increase coronary blood flow. Sublingual nitroglycerin possesses a powerful dilator effect on veins which reduces venous return and thereby the size of the heart and intra-myocardial tension; thus myocardial oxygen requirements are diminished. The beta-adrenergic receptor blocking drug, propranolol (Inderal(R)), inhibits sympathetic stimulation of the heart at rest and during exercise. Thus, myocardial oxygen requirements are diminished by the reduction in heart rate and diminished contractility. As a result of this latter action, cardiac output is reduced and thereby arterial pressure and intramyocardial tension is lowered. In patients with advanced heart disease and borderline cardiac compensation, propranolol is hazardous because it removes the availability of one of the important reserve mechanisms for maintaining cardiac compensation-the sympathetic support of the failing heart. The introduction of electrical stimulation of the carotid sinus nerves as a means of therapy in patients with angina pectoris has provided a powerful tool for the treatment of patients with refractory ischemic pain.
 ...
PMID:New trends in the treatment of angina pectoris. 498 Aug 81

In a double blind trial the authors studied the effect of beta-adrenoblocking agent Trimepranol (Spofa, Czechoslovakia), in 35 patients with ischaemic heart disease (IHD) associated with angina pectoris, and in another 42 patients they compared the effect of Trimepranol and Obsidan (GDR). The daily doses of Trimepranol and Obsidan averaged 80-100 mg and 160-200 mg respectively. In two thirds of the patients the diagnosis of IHD was confirmed by coronary arteriography. In 46 patients the authors examined the tolerance of physical exercise before and after 3 to 4 weeks of Trimepranol and Obsidan therapy. Trimepranol was effective in 81% and Obsidan in 83% of patients with angina pectoris of effort. The two drugs were distinctly less effective in patients with both effort and resting angina pectoris (54 and 64% respectively). Trimepranol treatment was associated with a higher incidence of side-effects such as bradycardia, arterial pressure decrease and bronchial spasm than Obsidan treatment.
 ...
PMID:Treatment of ischaemic heart disease with beta-adrenoblocking agents Trimepranol and Obsidan. 613 99

Obsidan effectiveness was examined in 42 coronary patients. Good clinical effect was achieved in 81% of patients with angina of effort and 64% of patients with angina of effort and angina at rest. Exercise tolerance increased in half of the patients. Radionuclide scintigraphy with 201Tl showed a reduction of exercise-induced transitory myocardial ischemia zones, a finding indicative of obsidan favourable effect on coronary microcirculation reserve.
 ...
PMID:[Effectiveness of obsidan in patients with ischemic heart disease and its effect on myocardial perfusion]. 635 30

Long-acting propranolol (Inderal LA) is a new formulation of propranolol that allows release of the drug in a controlled manner, so that the plasma concentration at 24 hr after dosing is greater with long-acting propranolol than with conventional tablets. A single dose of 160 mg of long-acting propranolol can produce cardiac beta-adrenoceptor blockade throughout a 24 hr period without variability due to multiple peak concentrations. It has been shown that this formulation is as effective in the treatment of angina pectoris, hypertension and hyperthyroidism as the standard formulation. Studies with long-acting propranolol in cardiac dysrhythmias are lacking. This new dosage form would be a means of simplifying dosing regimens and thereby hopefully enhancing patient convenience and compliance.
 ...
PMID:Long-acting propranolol (Inderal LA): pharmacokinetics, pharmacodynamics and therapeutic use. 636 3

TWELVE patients with moderately severe angina pectoris completed a double blind cross-over comparison of conventional propranolol (40 mg q.i.d.) and Inderal L.A. (160 mg once daily) with regard to therapeutic effectiveness, blood levels, compliance and patient acceptability.Exercise tolerance was assessed using standardised treadmill testing at 1, 2, 4, 8, 12 and 24 hours after the morning dose. The double placebo technique was used.Patient compliance was excellent for both regimes and no serious side effects were reported. No significant differences in exercise tolerance or blood levels were observed between the two treatments at any time.
 ...
PMID:Comparison of propranolol and inderal L.A. in patients with angina. 699 13

Selective coronarography and pharmacological test with intravenous administration of ergometrin have been carried out in 100 patients. The test permits one to demonstrate the vasospastic form of angina pectoris, which is encountered in patients with different degrees of lesions of the coronary arteries and different tolerance to exercise. Lack of coincidence in localization of ischaemic zones in the myocardium in tests with exercise and intravenous injection of ergometrin according to myocardium scintigraphy with 201Tl points to the possibility of existence of two forms of angina pectoris in the same patient, differing not only in the pathogenetic mechanisms but also in the localization of the ischaemic changes supervening in the myocardium. According to the data of echocardiography during the anginal attack with rise of the ST segment there is a more pronounced dilatation of the left ventricle cavity and decrease of the myocardial contractility than in the anginal attack with depression of the ST segment. In patients with spontaneous angina pectoris and rise of the ST segment corinfar exerted marked antianginal effect. Inderal was ineffective. In patients with angina pectoris and depression of the ST segment there was no difference between the two drugs.
 ...
PMID:[Role of the vasospastic factor in stenocardia in ischemic heart disease]. 706 83


1